Tempus AI Stock Jumps 9% After Introducing xM for Treatment Response Monitoring
Tempus AI stock rose more than 9% after announcing xM for treatment response monitoring, TRM, a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors.
xM for TRM is the newest addition to Tempus’ growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease. It is currently available for research use only, with clinical availability expected later this year.
“Our comprehensive monitoring portfolio is designed to support patients throughout the cancer treatment journey,” said Halla Nimeiri, MD, Chief Development Officer at Tempus. “We’re excited to introduce a new assay of molecular response for both physicians and biopharma researchers that can timely track changes of quantitative tumor fraction while patients receive ICI therapies.”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10